# Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

> **NCT01724359** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag, S.A.** · enrollment: 95 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT01724359
- **Lead sponsor:** Janssen-Cilag, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2013-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724359, "Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01724359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*